MAPK3 and breast carcinoma: In breast cancer cells, low-dose AGEs activate ERK1/2 and CREB1 to enhance cancer cell proliferation and migration (77, 78), and similar RAGE-dependent pro-proliferative and migratory effects were observed in the highly invasive breast cancer MDA-MB-231 cell line (79).